

DATA VISUALIZATION STRATEGIES FOR ANOMALY DETECTION

PhUSE SDE
09Nov2017



Copyright © 2017 Covance. All Rights Reserved





Agenda

- Introduction
- Defining the Challenge
- Data Anomaly Use Cases
- Working Group 3 Plan
- Call for Action

Introduction

WHY IS IT IMPORTANT?


- Transformative
- Interactive data visualizations
- Incorporating unsupervised anomaly detection
- Early detection and action



Data Anomaly Case 1

DATA QUALITY

Labs– xULN: Data Error



Other Data Anomaly Use Cases

SIGNAL DETECTION

- Safety Trend across patient groups within a study
- Data aggregated across studies for a given compound compared to norm

FRAUD DETECTION

- Distribution of Assessment Dates – By Site
- Event time to time event reported
- Distribution of Measurements

Working Group 3

DELIVERABLE GOAL AND PLANS

- Identify and recommend best practices for systematic approach to detecting anomalies
- Planning
 - Literature Review is ongoing
 - SME Guest Speakers Q4 2017 /Q1 2018
 - White Paper Comparison of Available Tools Q2 2018

Call for Action – Join Us

NEW MEMBERS ARE WELCOME!

Paul Schuette	FDA
Elena Rantou	FDA
Mitch Cooper	Eli Lilly and Company
Jasmine Sen	Bayer
Michael Rubison	Capish
Bhaskar Dutta	Astra Zeneca
Eric Herbel	Integrated Clinical Systems
Heather Stevens	Covance

Please contact Lauren White lauren@phuse.eu to join.